Mesothelioma drug Onconase status update

"Alfacell Corp. reported recently that company executives have met with officials from the U.S. Food and Drug Administration. At that meeting, FDA officials recommended that before the New Drug Application is submitted for Onconase, the drug should be subjected to another clinical trial involving patients with malignant mesothelioma that cannot be treated surgically (unresectable) " (2009-2-13)
Read more...